Back to RDEA Stock Lookup

Ardea Biosciences, Inc. (RDEA) – Corporate News

May 30, 2012 08:31 AM Ardea Biosciences (RDEA) Gets $7.5M Milestone from Bayer for MEK Inhibitor Development
Dec 19, 2011 08:01 AM Ardea (RDEA) Initiates Potenital Gout Treatment Lesinurad Phase 3
Sep 7, 2011 08:33 AM Ardea Biosciences (RDEA) Completes Positive End-of-Phase 2 FDA Meetings for Lesinurad
May 25, 2011 04:46 PM Ardea Biosciences (RDEA) Provides Additional Positive Data for Gout Treatment Lesinurad
Jan 10, 2011 08:12 AM Ardea Biosciences (RDEA) Receives $15M Milestone from Bayer
Jan 6, 2011 04:15 PM Ardea Biosciences (RDEA) Announces Positive Phase 2b Data for RDEA594 in Allopurinaol-Refractory Gout Patients
Jun 18, 2010 08:05 AM Ardea (RDEA) Issues Additional Data from Phase 2 Trial for RDEA594
Dec 1, 2009 08:15 AM Ardea Biosciences (RDEA) Announces Positive Results from RDEA594 Pharmacodynamic Study
Oct 19, 2009 08:26 AM Ardea Bio (RDEA) Results Positive in Phase IIa RDEA594 Study; Will Announce at ACR/ARHP Scientific Meeting
Apr 20, 2009 04:16 PM Ardea Biosciences (RDEA) Reports Positive Results from Phase 1 Study of RDEA594 and Phase 2a Study of RDEA806
Jan 14, 2009 08:54 AM Ardea Biosciences (RDEA) Announces Resale of Up to 3.42M Shares
Jan 12, 2009 09:59 AM Ardea Biosciences (RDEA) Reports Positive Results from Phase 1 Trial of RDEA594
Oct 16, 2008 08:25 AM Ardea Biosciences (RDEA) Initiates a Phase 1/2 Study of RDEA119, its Lead MEK Inhibitor
Oct 7, 2008 08:27 AM Ardea Biosciences (RDEA) Presents Preclinical Data on Lead MEK Inhibitor, RDEA119, at ACG 2008
Jul 9, 2008 08:56 AM Ardea Biosciences (RDEA) Receives Regulatory Approval to Begin Phase 2a Trial on RDEA806 for Gout
May 22, 2008 08:19 AM Ardea (RDEA) Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

Back to RDEA Stock Lookup